;
Skip to main content
Home > The Daily Extra > Politics & Policy

Chronological Index of : Politics & Policy

 Current Issue
  • POLITICS & POLICY: Arizona voters pass right-to-try measure

    Arizona voters passed Proposition 303, a right-to-try ballot measure that gives terminally ill patients access to experimental therapies not yet approved by FDA, with 78.3% of the vote.The measure says an eligible …

    Published on 11/6/2014
  • POLITICS & POLICY: FDA unlikely to pull conventional opioids

    Opioid abuse-deterrence technology is in its "infancy" and FDA is unlikely to remove opioids that lack abuse-deterrence features from the market soon, Janet Woodcock, director of FDA's Center for Drug Evaluation and …

    Published on 11/6/2014
  • POLITICS & POLICY: Valeant and Pershing Square may vote

    The U.S. District Court for the Central District of California ruled that activist Pershing Square Capital and Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) may vote shares of Allergan Inc. (NYSE:AGN) …

    Published on 11/5/2014
  • POLITICS & POLICY: FDA asks where to add patient perspectives

    FDA is looking to expand its patient-driven drug development process by inviting stakeholders to weigh in on "strategies to solicit the views of patients during the medical product development process and consider the …

    Published on 11/3/2014
  • POLITICS & POLICY: MHRA names Rawlins chairman

    The U.K.'s Medicine and Healthcare Products Regulatory Agency (MHRA) named Michael Rawlins chairman for a three-year appointment effective Dec. 1.He succeeds Gordon Duff, who said he would step down after he was elected…

    Published on 11/3/2014
  • POLITICS & POLICY: Patient groups, PhRMA to huddle on expanded access

    Four patient advocacy organizations and the Pharmaceutical Research and Manufacturers of America will discuss compassionate use on Dec. 10 at an invitation-only workshop in Washington entitled "Role of Investigational …

    Published on 11/3/2014
  • POLITICS & POLICY: Regulator tracks

    Joseph Griffin joined regulatory consulting firm Greenleaf Health LLC as EVP of drug and biological drug products. He was associate director for policy development in the Office of Medical Policy at FDA's Center for …

    Published on 10/31/2014
  • POLITICS & POLICY: Veloxis respectfully begs to differ with FDA

    Veloxis Pharmaceuticals A/S (CSE:VELO) plunged DKK0.63 (31%) to DKK1.40 on Friday after the company said FDA's tentative approval of immunosuppressant Envarsus XR tacrolimus will not become finalized until exclusivity …

    Published on 10/31/2014
  • POLITICS & POLICY: EMA issues biosimilar development guidance

    EMA issued final guidance outlining general principles for developing biosimilars in the EU with a handful of changes from draft guidance issued in May 2013 (see BioCentury Extra, May 2, 2013).The final guidance adds …

    Published on 10/29/2014
  • POLITICS & POLICY: Rep. McCaul outlines compassionate access bill

    Rep. Michael McCaul (R-Texas) plans to introduce compassionate access legislation that would impose new requirements on drug developers and establish rights for patients. McCaul summarized the legislation and his …

    Published on 10/29/2014
  • POLITICS & POLICY: Senators seek to incentivize Ebola research

    Sens. Tom Harkin (D-Iowa) and Lamar Alexander (R-Tenn.) plan to introduce a bill that would add Ebola to the list of eligible diseases under FDA's Priority Review voucher program for tropical diseases. Upon FDA approval…

    Published on 10/29/2014
  • POLITICS & POLICY: WHO wants trial disclosure deadlines

    The World Health Organization is calling for a strict timeline for public disclosure of clinical trial results, citing analysis showing that "a significant proportion of healthcare research remains unpublished," and its…

    Published on 10/23/2014
  • POLITICS & POLICY: FDA backs further study of kidney biomarkers

    FDA issued its first Letter of Support for two kidney biomarkers identified by the Predictive Safety Testing Consortium (PSTC) of the Critical Path Institute (C-Path).Elevated levels of the two biomarkers, osteopontin (…

    Published on 10/21/2014
  • POLITICS & POLICY: U.S. calls pathogen research timeout

    The White House Office of Science and Technology Policy (OSTP) and HHS announced the U.S. government has halted funding for "gain of function" (GOF) research that could increase the pathogenicity or respiratory …

    Published on 10/20/2014
  • POLITICS & POLICY: Looking ahead at PTO

    President Obama's nomination of Michelle Lee as director of the U.S. Patent and Trademark Office marks a victory of Silicon Valley tech interests over the U.S. biopharmaceutical industry in their battle for control over…

    Published on 10/17/2014
  • POLITICS & POLICY: CDER restructures for product quality initiative

    Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, announced that CDER will restructure to implement her plan to modernize drug quality oversight through a "super-office" that will cover all …

    Published on 10/16/2014
  • POLITICS & POLICY: White House elevating Google veteran at PTO

    The Obama administration continued to reinforce its ties to Silicon Valley with the nomination of Michelle Lee to be director of the U.S. Patent and Trademark Office. Lee, who also would be under secretary for …

    Published on 10/16/2014
  • POLITICS & POLICY: SCOTUS challenges on Teva patent case

    U.S. Supreme Court justices on Wednesday voiced skepticism about arguments from both sides in the petition by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to overturn an appeals court decision that invalidated the …

    Published on 10/15/2014
  • POLITICS & POLICY: USTR launches review of IPR in India

    The Office of the U.S. Trade Representative (USTR) announced its planned review of intellectual property rights (IPR) in India. The review, promised in April when USTR published its "2014 Special 301 Report," noted …

    Published on 10/13/2014
  • POLITICS & POLICY: FDA finalizes 5-year exclusivity for NCE combos

    FDA issued final guidance under which it will grant five years of exclusivity to fixed-dose combination products that have at least one new active moiety. Previously, FDA interpreted its exclusivity regulations to mean …

    Published on 10/10/2014
  • POLITICS & POLICY: Exchange pharmacies using specialty drugs more often

    Patients enrolled in public health exchanges under the Affordable Care Act are using more generics than patients in traditional health plans, but also are prescribed a larger proportion of specialty drugs, especially …

    Published on 10/9/2014
  • POLITICS & POLICY: Tufts finds value for money in specialty drugs

    A study published in Health Affairs suggests that despite their higher costs, specialty drugs can offer "reasonable value for money" compared to traditional drugs, although the treatment gains from specialty treatments …

    Published on 10/8/2014
  • POLITICS & POLICY: Biosimilar workflow growing at CDER

    FDA's Center for Drug Evaluation and Research on Tuesday told BioCentury it has received 78 requests for initial meetings to discuss biosimilar development programs for 14 different reference products. CDER also said it…

    Published on 10/7/2014
  • POLITICS & POLICY: FDA issues new patient-focused nominations

    FDA is seeking public comments on disease areas it has nominated for future meetings of its patient-focused drug development (PFDD) initiative. PFDD aims to obtain patient perspectives on specific diseases and …

    Published on 10/7/2014
  • POLITICS & POLICY: FDA to review REMS for Soliris

    FDA's Drug Safety and Risk Management Advisory Committee (DSaRM) will meet on Nov. 18 to discuss the REMS for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). The committee is seeking public …

    Published on 10/7/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993